The U.S. Food and Drug Administration (FDA) regulates the safety, effectiveness, sales and distribution of cancer profiling tests. On November 15, 2017, FDA authorized Memorial Sloan Kettering Cancer Center’s (MSK) IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) tumor profiling test. The test is capable of high throughput screening and identification of a higher number of mutations using biomarkers of different cancer types.
Get report Sample Copy @ https://www.factmr.com/connectus/sample?flag=S&rep_id=358
Along with this new test authorization, FDA recognized wider acceptance of cancer profiling tests for better treatment of cancer and streamlined policy framework for the efficient review process and faster availability of NGS-based cancer profiling tests. The new framework allows review of the tests by accredited third-party to reduce the test developer’s burden and streamline ensuing regulatory assessment procedures. This step has paved a way for NGS-based cancer profiling tests manufacturers to elude tedious regulatory process of authorization and faster entry to the market.
Cancer Profiling Complements Ongoing Precision Oncology R&D Activities
Traditionally treated on the basis of body location with a one-size-fits-all approach, cancer treatment is evolved significantly wherein precision medicine has aided in better cancer management. Identification of the target mutation with cancer profiling assists in determining highly specific drug that delivers long-lasting remission and expansion of lifetime.
Personalized medicine approach in cancer treatment involves genetic information of an individual and his or her cancer cell profile. In addition, lifestyle, diet, microbiome and other information of an individual is also covered while determining the personalized treatment approach. As cancer profiling helps in delivering genetic information of cancer cells, ongoing R&D activities in the field of precision oncology present lucrative avenues for cancer profiling manufacturers.
Rising Cancer Burden Necessitates Utilization of Cancer Profiling Tests
According to the World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for nearly 9.6 million deaths in 2018 worldwide. While major strides are being made to prevent cancer development, the medical community still need to address the estimates of new cancer cases projected in coming years. WHO estimates the global burden of cancer to have risen to 18.1 million new cases in 2018.
As the incidences of rare cancer continue to rise, personalized medicine is providing promising results in cancer treatment. Cancer profiling is aiding the personalized treatments by providing the identification of specific gene mutation and use of targeted therapies.
Development of Datasets and Interpretation Tools Increases Cancer Profiling Precision
Major R&D investments in the cancer profiling market are being utilized in developing platforms for genomic data and clinical information to enhance the current capabilities of genomic profiling tests for different types of cancers. The current landscape of cancer profiling is facing challenges of clinical translations due to lack of sufficient consensus for treatment development and time-consuming interpretation.
With the growing emphasis on collaborative treatment to address cancer treatment issues effectively, development of common datasets is underway which can be used to interpret cancer profiling results and improve the treatment of cancer patients.
Browse Complete Research report with TOC @ https://www.factmr.com/report/358/cancer-profiling-market
The Blood Profiling Atlas in Cancer (BloodPAC) Consortium launched a dataset for liquid biopsies and announced public release and accessibility of initial dataset in February 2018. Max Cancer Center in India recently published development of a web-based genome profiling interpretation tool – DrAV tool. The tool provides a platform for genomic data extraction and analysis of clinical information to aid precision oncology and cancer profiling processes.
Limitations in Identification of Predictive Biomarkers to Hider Cancer Profiling Test Developments
As genomic instability and acquisition of mutations are the hallmarks of cancer, tumor heterogeneity continues to pose challenges for the identification, testing and development of cancer biomarkers. These challenges reach to drug development landscape wherein their implementation in clinical drug trials is advancing at a staggering pace.
For these reasons, the landscape of cancer therapy seeks potential strategies for the development of robust biomarkers that complements the evolving cancer alterations, thereby enabling efficient tumor biopsies using cancer profiling. While ongoing cancer therapeutic scenario is lagging behind in biomarker development, considerable investments are in pipeline and their outcome is expected to aid in the progress of cancer profiling landscape in the future.
Cancer Profiling Market - Competitive Landscape
In the competitive landscape of the cancer profiling market report, competition scenario of the market is explained in terms of a dashboard view of all the key players and their relative presence in the global market. The section has also identified prominent players in cancer profiling market, emerging players, mid-size players and other key players in the cancer testing market.
The section of company profiles delivers vital information such as product offerings, products in clinical trials and company developments. Few of the profiles players in the cancer profiling market report include F. Hoffmann La Roche Ltd, Illumina Inc, QIAGEN, Thermo Fisher Scientific Inc, Abbott, Nanostring Technologies Inc, Siemens AG, HTG Molecular Diagnostics, Inc, Perkin Elmer Inc, Agilent Technologies Inc, Negenomics Laboratory Inc, Genomic Health, Biogenex and Pacific Biosciences of California, Inc.
The cancer profiling marketplace is marked by significant investments in R&D aimed at getting clinical approvals. Multiple cancer profiling tests received FDA approvals in recent past. For instance, in November 2017, FDA approved the IMPACT developed at the Memorial Sloan Kettering Cancer Center. It is an in vitro NGS-based diagnostic test with the capacity to identify a higher number of tumor biomarkers and rapid identification of mutations in 468 unique genes.
In December 2017, FoundationOne CDx (F1CDx) genomic cancer profiling test that can identify cancer-associated alterations in 324 genes and two type of genomic signature in any solid tumor.
Send an Enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=358
In August 2018, Caris Life Sciences® announced the company’s selection by the Hoosier Cancer Research Network to perform cancer profiling for a new Phase II bladder cancer clinical trial of HCRN GU16-257.
About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
